 "Lupin Pharma's US-based arm recalls blood pressure tablets in US market")
Pharmaceuticals firm Lupin Ltd on Thursday said its US-based arm is recalling four lots of Quinapril tablets used to treat high blood pressure due to the presence of a nitrosamine impurity.
Lupin Pharmaceuticals Inc, the company's wholly-owned arm, is recalling the said tablets due to the presence of a nitrosamine impurity, N-Nitroso-Quinapril, observed in recent testing above the acceptable daily intake (ADI) level, Lupin Ltd said in a regulatory filing.
"To date, Lupin has received no reports of illness that appear to relate to this issue," it said, adding it discontinued marketing of Quinapril tablets in September 2022.
Quinapril tablets of strengths 20mg and 40mg packaged in separate 90 count bottles were distributed nationwide in the US to wholesalers, drug chains, mail order pharmacies and supermarkets, it added.
The filing further said Lupin Pharmaceuticals Inc is notifying its wholesalers, distributors, drug chains, mail order pharmacies and supermarkets by phone and through recall notification and is arranging for the return of all the recalled product lots while asking them to discontinue distribution of the recalled lots immediately.
The company, however, advised patients taking the Quinapril tablets "to continue taking their medication and contact their pharmacist, physician, or medical provider for advice regarding an alternative treatment".
"This recall is being conducted with the knowledge of the US Food and Drug Administration," it added.
The company said nitrosamines are common in water and foods, including cured and grilled meats, dairy products and vegetables.
While everyone is exposed to some level of nitrosamines, these impurities may increase the risk of cancer if people are exposed to them above acceptable levels over long periods of time, it added.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app